Single Chain Antibody Patents (Class 424/135.1)
-
Patent number: 9028817Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.Type: GrantFiled: October 25, 2010Date of Patent: May 12, 2015Assignee: Glaxo Group LimitedInventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
-
Publication number: 20150125385Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.Type: ApplicationFiled: March 15, 2013Publication date: May 7, 2015Inventors: George Coukos, Chunsheng Li
-
Publication number: 20150125449Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.Type: ApplicationFiled: May 8, 2013Publication date: May 7, 2015Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter Von Kreudenstein
-
Patent number: 9023353Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.Type: GrantFiled: March 13, 2013Date of Patent: May 5, 2015Assignee: The Board of Trustees of the University of ArkansasInventors: Samuel Michael Owens, Ralph Henry, Alicia Brown
-
Patent number: 9023348Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.Type: GrantFiled: November 17, 2009Date of Patent: May 5, 2015Assignee: Technion Research & Development Foundation LimitedInventors: Yoram Reiter, Cyril Cohen
-
Publication number: 20150118153Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.Type: ApplicationFiled: May 6, 2013Publication date: April 30, 2015Inventors: Wayne A. Marasco, Jianhua Sui, Quan Zhu, De-Kuan Chang
-
Publication number: 20150118232Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: ApplicationFiled: September 26, 2014Publication date: April 30, 2015Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Publication number: 20150118230Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: February 15, 2013Publication date: April 30, 2015Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Publication number: 20150118231Abstract: The present invention relates to methods and compositions for treating neurodegenerative conditions, such as Alzheimer's Disease, by systemic administration of specific apoE4 antibodies.Type: ApplicationFiled: May 7, 2013Publication date: April 30, 2015Inventor: Daniel Michaelson
-
Publication number: 20150118156Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.Type: ApplicationFiled: December 23, 2014Publication date: April 30, 2015Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
-
Patent number: 9017683Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: GrantFiled: May 3, 2013Date of Patent: April 28, 2015Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Hiroyuki Aburatani, Lilin Zhang, Keisuke Ishii, Katsushi Kouda, Aya Sakamoto, Keiko Katsumi, Hiroshi Onishi, Yoko Kayukawa
-
Patent number: 9017671Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).Type: GrantFiled: October 25, 2012Date of Patent: April 28, 2015Assignee: Genentech, Inc.Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
-
Publication number: 20150110786Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.Type: ApplicationFiled: March 7, 2013Publication date: April 23, 2015Inventors: Deborah Fass, Iris Grossman, Tal Ilani, Assaf Alon
-
Publication number: 20150110787Abstract: A polypeptide, antagonist, and antibody that specifically bind to and inhibit VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.Type: ApplicationFiled: October 20, 2014Publication date: April 23, 2015Inventors: Seok Kyun KIM, Sang Yeul HAN, Kwang Hoon LEE, Kyung Eun KIM
-
Publication number: 20150110783Abstract: Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.Type: ApplicationFiled: December 18, 2014Publication date: April 23, 2015Applicants: XOMA Technology Ltd., NOVARTIS AGInventors: Xiaofeng Lu, Bao-Lu Chen, Kidisti Araya, Augustus Okhamafe
-
Patent number: 9012609Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: GrantFiled: August 12, 2011Date of Patent: April 21, 2015Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Haren Arulanantham, Thil Dinuk Batuwangala, Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
-
Patent number: 9011858Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.Type: GrantFiled: May 15, 2013Date of Patent: April 21, 2015Assignee: ZymoGenetics, Inc.Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
-
Patent number: 9005614Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: GrantFiled: November 22, 2010Date of Patent: April 14, 2015Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
-
Patent number: 8999331Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.Type: GrantFiled: October 24, 2012Date of Patent: April 7, 2015Assignee: AbbVie Inc.Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
-
Patent number: 9000131Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.Type: GrantFiled: July 30, 2009Date of Patent: April 7, 2015Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Isin N. Geren
-
Patent number: 8999330Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.Type: GrantFiled: July 13, 2012Date of Patent: April 7, 2015Assignee: Alderbio Holdings LLCInventor: Jeffrey T. L. Smith
-
Publication number: 20150093384Abstract: The present invention relates to methods and systems for administering antibody therapeutic agents. The methods include administering one or more (e.g., two or three) binding agents, wherein each of the binding agents has a binding region that is specific to a portion of a disease agent and one or more copies of a tag. The binding agents can be specific to one or more portions of the same or different disease agents. The tag is the same for each of the binding agents. The methods include administering an anti-tag antibody, wherein the anti-tag antibody has an anti-tag region that is specific to the tag, and can have an immunoglobulin (e.g., IgA, IgD, IgE, IgG, and IgM.). Disease agents include bacterial proteins, viral proteins, cancer cells, and proteins or toxins produced therefrom. In particular, the present invention includes methods and systems for binding agents that are specific to neurotoxins that cause botulism.Type: ApplicationFiled: September 12, 2014Publication date: April 2, 2015Inventors: Charles B. Shoemaker, Jorge A. Sepulveda Toepfer, Jean Mukherjee
-
Patent number: 8992908Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.Type: GrantFiled: November 23, 2011Date of Patent: March 31, 2015Assignee: Alderbio Holdings LLCInventors: Jeffrey T.L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
-
Patent number: 8992909Abstract: The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.Type: GrantFiled: February 22, 2012Date of Patent: March 31, 2015Assignee: Board of Trustees of the University of ArkansasInventors: John D Shaughnessy, Jr., Bart Barlogie, Ya-Wei Qiang
-
Patent number: 8992921Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.Type: GrantFiled: March 17, 2014Date of Patent: March 31, 2015Assignee: Syracuse UniversityInventors: Robert P. Doyle, Joshua J. Lensbouer
-
Patent number: 8992913Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.Type: GrantFiled: June 12, 2013Date of Patent: March 31, 2015Assignee: Pfizer Inc.Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
-
Patent number: 8992904Abstract: The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.Type: GrantFiled: November 24, 2010Date of Patent: March 31, 2015Assignee: Alderbio Holdings LLCInventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
-
Patent number: 8992911Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: GrantFiled: November 6, 2012Date of Patent: March 31, 2015Assignee: UCB Pharma S.A.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Patent number: 8992924Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: May 17, 2011Date of Patent: March 31, 2015Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20150079089Abstract: Disclosed herein are methods and compositions for modulating neovascularization. The disclosed compositions find particular use in the treatment of uterine cancers, specifically endometrial cancers.Type: ApplicationFiled: February 6, 2013Publication date: March 19, 2015Inventors: Madhuri Wadehra, Jonathan Braun, Lynn K. Gordon
-
Publication number: 20150079092Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: September 24, 2014Publication date: March 19, 2015Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20150079091Abstract: Mutations in calreticulin are discovered to be linked to myeloid malignancies. Disclosed are genomic sequences, cDNA sequences, mRNA sequences and protein sequences of mutant calreticulin that are linked to myeloid malignancies. Also disclosed are methods for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also disclosed are related compositions, kits and methods, including the medical use of inhibitors of mutant calreticulin.Type: ApplicationFiled: September 15, 2014Publication date: March 19, 2015Applicant: CeMM - FORSCHUNGSZENTRUM FÃœR MOLEKULARE MEDIZIN GmbHInventors: Robert KRALOVICS, Thorsten Klampfl, Heinz Gisslinger
-
Publication number: 20150079090Abstract: The present invention relates to a therapeutic agent for inflammation in which histone is involved, the agent comprising a monoclonal antibody or an antigen binding fragment thereof which binds to a peptide consisting of an amino acid sequence represented by SSVLYGGPPSAA (SEQ ID NO:1) or a conjugate of the peptide and a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 22, 2013Publication date: March 19, 2015Inventors: Shuji Sato, Takeshi Goto, Naoya Ohmori, Kueichen Chiang, Yayoi Shimada, Masafumi Inomata, Toru Kusano, Takahiro Hiratsuka, Takayuki Noguchi, Satoshi Hagiwara
-
Publication number: 20150079088Abstract: The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: July 25, 2014Publication date: March 19, 2015Inventors: Henry Bernard Lowman, James William West, Sherry Lynn La Porte, Bryan Allen Irving, Daniel Robert Hostetter, Chihunt Wong
-
Patent number: 8980270Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: GrantFiled: January 14, 2014Date of Patent: March 17, 2015Assignee: iPierian, Inc.Inventors: Irene Griswold-Prenner, Nancy E. Stagliano, Vu Dang
-
Patent number: 8980257Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.Type: GrantFiled: May 17, 2011Date of Patent: March 17, 2015Assignee: Medical & Biological Laboratories Co., Ltd.Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
-
Patent number: 8980265Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumor tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimized for the respective indication/tumor entity.Type: GrantFiled: March 14, 2003Date of Patent: March 17, 2015Assignee: BioNTech AGInventors: Klaus Pfizenmaier, Harald Wajant, Dieter Moosmayer, Thomas Wuest
-
Publication number: 20150071853Abstract: The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma.Type: ApplicationFiled: May 14, 2014Publication date: March 12, 2015Inventors: Jean Elie KADOUCHE, Emmanuelle Sabbah-Petrover, Olivier Chose
-
Publication number: 20150071926Abstract: A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the ?2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.Type: ApplicationFiled: February 26, 2013Publication date: March 12, 2015Inventors: Andrzej Fertala, Andrzej Steplewski
-
Patent number: 8974783Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: February 7, 2014Date of Patent: March 10, 2015Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8974792Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: April 6, 2012Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Patent number: 8968736Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.Type: GrantFiled: August 21, 2013Date of Patent: March 3, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
-
Patent number: 8968732Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: December 19, 2013Date of Patent: March 3, 2015Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8968735Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.Type: GrantFiled: March 7, 2013Date of Patent: March 3, 2015Assignees: Mayo Foundation for Medical Education & Research, Acorda Therapeutics, Inc.Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
-
Patent number: 8969040Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.Type: GrantFiled: July 2, 2013Date of Patent: March 3, 2015Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
-
Patent number: 8968733Abstract: A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition.Type: GrantFiled: February 19, 2010Date of Patent: March 3, 2015Assignee: Sofradim ProductionInventor: Sebastien Ladet
-
Publication number: 20150056200Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.Type: ApplicationFiled: June 30, 2014Publication date: February 26, 2015Inventors: Jasbir Seehra, Ravindra Kumar, Jennifer Lachey, Alan Koncarevic
-
Publication number: 20150056159Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.Type: ApplicationFiled: April 16, 2013Publication date: February 26, 2015Applicant: UNIVERSIT T STUTTGARTInventors: Roland Kontermann, Oliver Seifert, Aline Plappert
-
Publication number: 20150056201Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: October 30, 2014Publication date: February 26, 2015Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Patent number: 8961981Abstract: Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular junction. Compositions include a neuromuscular junction targeting peptide coupled to a therapeutic agent. Compositions may further include a linker peptide. Methods for targeting therapeutic agents to neuromuscular junctions and treating diseases and conditions affecting the neuromuscular junction include administering a composition including a neuromuscular junction targeting peptide coupled to a therapeutic agent.Type: GrantFiled: June 19, 2012Date of Patent: February 24, 2015Assignee: Saint Louis UniversityInventors: Henry Kaminski, Linda Kusner, Namita Satija